Jeremy K. Bridge-Cook

Luminex Corp. develops, manufactures and markets proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. The firm's products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments. The company was founded by Mark B. Chandler and Van S. Chandler in May 1995 and is headquartered in Austin, TX.

Tm Bioscience Corp. developed DNA-based diagnostics tests. It developed a suite of genetic tests that include tests for genetic disorders, drug metabolism and infectious diseases. Tm Bioscience was founded on December 19, 1980 and was headquartered in Toronto, Canada.

Luminex Molecular Diagnostics, Inc. develops DNA based diagnostics tests and software solutions, which include genetic tests for disorders, drug metabolism and infectious diseases. The firm’s products include P450-2D6, P450-2C9, P450-2C19, AJ panel and CFTR. The company was founded in March 2007 and is headquartered in Toronto, Canada.

GenePOC, Inc. develops rapid molecular devices to detect genes at point-of-care. Its product includes an integrated portable instrument for the prevention and early detection of infectious diseases based on a centripetal technology platform. Its product also includes GenePOC disposable, a device for performing nucleic acid-based diagnostics at POC. The company’s products are also used for infectious disease, rapid food microbiology, and human pharmacogenetic testing applications. The company was founded by Michel G. Bergeron in 2007 and is headquartered in Quebec, Canada.

The Ontario Bioscience Industry Organization is a membership organization that engages in strategy, programming, policy development, and advocacy. The non-profit company is based in Toronto, Canada. The Canadian company was founded by Simon Goulet. Maura Campbell has been the CEO of the company since 2021.

Rna Diagnostics, Inc. operates as a cancer diagnostics company which builds a platform of prognostic biomarker tools to help improve the lives of patients undergoing chemotherapy. The firm develops prognostic biomarker tools to improve the lives of women undergoing chemotherapy for breast cancer. It provides The RNA Disruption Assay (RDA), which provides physicians with an evaluation of how individual patients are responding to chemotherapy. The company was founded by Kenneth P. H. Pritzker in 2010 and is headquartered in Toronto, Canada.